Insigneo Newsletter Spring 2015 - Showcase Edition

Issue 1: Spring 2015“THE SHOWCASE EDITION”

BIG DATA PROJECT NEWS EVENTS ROUNDUP

2 INSIGNEO NEWS ISSUE 1 SPRING 2015

Inside Issue 104 News Events & Awards

07 Introducing... Polaris

08 Project Focus VIRTUheart

10 The Feature Big Data

12 Researcher Focus Damien Lacroix

16 Showcase Timetable

18 VPH InstituteAdriano Henney

The Pam Liversidge BuildingSir Frederick Mappin Building

Mappin StreetSheffield

S1 3JD

+44 (0) 114 222 0162 /5 /[email protected]

@insigneo

Cover: “Stem cells on a biomaterial with hierarchical porosity.”

Robert Owen, PhD student, Materials Science. Supervisors; Reilly, Lacroix, Bellantuono and Claeyssens.

With thanks to Dr. Nicola Green of the Kroto Imaging Facility.

10

08

1207

CONTENTS

INSIGNEO NEWS ISSUE 1 SPRING 2015 3

Welcome

Insigneo: a coalition of the willing. When we explain how Insigneo works, we frequently use the expression “coalition of the willing”. In spite of being hijacked by the Bush administration for the first Iraq war, I think it is a beautiful expression. It means that we work together by choice, that we share effort and resources to the extent each of us sees appropriate.

But there is another expression that is very important: “united we stand, divided we fall”. I am fully aware that the archetypical academic could be described as individualist and anarchic; it comes with the territory. But current trends regarding higher education in the UK, especially in relation to research, suggest clearly that universities need

to focus, ensuring that most of their research falls into a small number of public narratives. This allows an institution to be recognised as a national leader in a particular area.

So we need to close ranks and make our shared vision of a predictive medicine strong and articulated. Our annual Showcase is the perfect occasion to reinforce this coalition, to establish new collaborations, understand better what others within Insigneo do and get more involved in its governance and in the development of shared resources. “Divided we fall, Insigneo we stand.”

Professor Marco Viceconti, Executive Director InsigneoMay 2015

“Our annual Showcase is the perfect occasion to reinforce this coalition and to establish new collaborations”

THE INSIGNEO TEAM BASED IN THE PAM LIVERSIDGE BUILDING


News RoundupNEWS

Major highlights from all the Insigneo projects, students and researchers

Sheffield Hospitals Charity has partnered with the Insigneo Institute to fund four innovative research projects that bring together clinicians from the Sheffield Teaching Hospitals with researchers from the University of Sheffield in order to use the latest research methodologies to address clinical needs.

The programme, which has just entered its third round, is funding three six-month bursaries and one three-year PhD scholarship. The successful projects were chosen for their potential to impact clinical practice and improve patient experience. For a full list of the successful bursaries, see www.insigneo.org

Bursary collaboration between Sheffield Hospitals Charity and Insigneo

Insigneo member Professor Alex Frangi, of CISTIB at the University of Sheffield has been awarded an EPSRC grant worth £1.3m to characterise and quantify early differential alteration in brain blood transport with a novel MRI technique. The OCEAN project will draw on techniques of neuropathology, neuroimaging and biophysics to identify biomarkers of disease onset and progression to better understand the effects of various drugs and treatments.

£1.3m for research into brain blood transport

Insigneo members’ awards and achievements Congratulations to Insigneo members Professor Richard Eastell and Dr. Gwendolen Reilly for their notable achievements. Professor Eastell was awarded the Frederic C. Bartter Award for outstanding clinical investigation in disorders of bone and mineral metabolism. Richard becomes one of only two

people working in the UK in the past 26 years to be awarded this most important accolade for clinical research into bone disease. Dr. Reilly was elected as President of the European Society of Biomechanics and becomes the first woman - as well as the third Insigneo member - to hold the role.

PROFESSOR EASTELL WITH HIS AWARD

L-R: P. LAWFORD, D. REYNOLDS & H. SHENTON


System to support treatment of back pain developedA clinical support system which will help clinicians treat patients with lower back pain has been developed thanks to research conducted in association with the Insigneo Institute for in silico medicine. The MySpine™ software system combines MR and CT images to generate personalised models of the lower spine. Using state-of-the-art in silico methods, three potential treatment options - discectomy, spinal fusion and a conservative treatment such as physiotherapy - can be virtually trialled. By simulating an ageing process, the impact of each treatment can be accurately assessed. Once validated for clinical use, this information will aid clinicians in choosing the best treatment for patients with lower back pain - a condition which affects up to 80% of the population at some point in their lives.

The €4m EC-funded project, which ran from 2011 to late 2014, met for its final technical meeting on 26th and 27th August 2014 in Buxton, near Sheffield. Representatives from each of the seven project partners met in the Chatsworth Room at the Palace Hotel, Buxton to evaluate the complex technical outputs and to discuss the work that will be taken forward into clinical practice.

The results have been very impressive and highly encouraging. The project has identified key characteristics that seem to offer clinically-relevant insights into the consequences of different interventions for the future health of patients, and the work to exploit these outputs will now be taken further; it is hoped that the MySpine™ software system will be helping patients lead better lives before too long.

MySpine™will aid clinicians to select the best treatment for lower back pain - a condition which effects up to 80% of the population

View the MySpine project video at www.insigneo.org


EventsEVENTS

Out and about with Insigneo

1

2 3

4

5

6

1. Enjoying the views in Rome with the Avicenna Project 2. Creative brainstorming at the MultiSim Workshop 3. Gwen Reilly taking over as President of the European Society of Biomechanics 4. Fundraising cakes at the MacMillan coffee morning 5. The Insigneo General Assembly 6. Taking a break at the Christmas lunch


INTRODUCING

POLARIS£7.5 million award is taking state-of-the-art lung research to the next level

World leading lung research, undertaken at the University of Sheffield and associated with the Insigneo Institute, has received a welcome boost of £7.5 million from the Medical Research Council and British Heart Foundation. The grant will help the POLARIS project, led by Professor Jim Wild of the Academic Unit of Radiology - and Insigneo member, expand its groundbreaking image acquisition and processing facilities in Sheffield, turning the UK into the leading nation in the area of diagnostic pulmonary medicine. The award is part of a £230 million grant for technologies, announced by the Chancellor of the Exchequer, George Osborne, in October 2014.

Professor Wild’s Pulmonary, Lung and Respiratory Imaging Sheffield (POLARIS) project uses state-of-the-art techniques to produce highly detailed images of patients’ lungs, without relying on radiation. By using hyperpolarised gases, the POLARIS team creates functional images of the lungs of patients affected by conditions such as smoking, cystic fibrosis, emphysema, pulmonary hypertension and asthma.

The images, which are more detailed than those created using conventional methods, are created when a patient inhales a small amount of a noble

gas, such as Helium-3 or Xenon-129. Using high power lasers, the gases are hyperpolarised in a process called ‘optical pumping’. The MRI images can then be used to help clinicians identify early signs of lung disease and other lung conditions. Several technical barriers, such as the ease of polarisation of the gases and the additional hardware required for the MRI scanners, still need to be overcome before this technology can become routinely used in the clinic.

Professor Wild said: “this grant will allow continued research into MRI scanner hardware and image acquisition methods and their clinical translation, ensuring Sheffield and the UK lead in this important area of diagnostic pulmonary medicine. The new image processing laboratory will allow us to process large volumes of digital imaging data for phenotyping pulmonary diseases together with computational modelling approaches, which are being pioneered in the Insigneo Institute for in silico medicine.”

A pair of healthy lungs (L) and a pair effected by smoking (R)

VIRTUheart


PROJECT FOCUS

Going into hospital for a procedure is never pleasant. At best, it is an inconvenience, at worst, undergoing surgery or even an assessment can be anxiety inducing, uncomfortable, invasive and often leave the patient needing a lengthy period of recovery. Anything which can be done to reduce this burden - on the patient, but also on hospital resources - is a welcome development.

VIRTUheart, a research project coordinated by the University of Sheffield and affiliated to the Insigneo Institute, has developed technology to improve the process for patients

undergoing assessment for coronary artery disease. By replacing an invasive procedure - which involves inserting a wire into the patient’s artery - with in silico methods, the VIRTUheart technology ensures the process is safer for the patient. By avoiding the administration of drugs with potentially unpleasant side effects, it also ensures that the procedure is easier for the patient to endure. It is good news for hospital accountants too, as the improved technique reduces the cost of the procedure, both by eliminating the need for additional hardware and significantly reducing the time to conduct the assessment.

By replacing an invasive procedure with in silico methods,VIRTUheart ensures the process is safer for the patient.

Technology developed in association with Insigneo will help ease the burden on patients undergoing assessment for coronary artery disease


Dr Paul Morris, a cardiology doctor from Sheffield Teaching Hospitals, who works on the VIRTUheart project explains: “VIRTUheart provides important clinical information for doctors when making decisions about how to treat coronary artery disease. It computes intra-coronary physiology and virtual fractional flow reserve (vFFR) from angiogram images of the coronary arteries. It does this by using the ANSYS-CFX computational fluid dynamics (CFD) software to calculate changes in blood pressure, which occur within diseased coronary arteries, rather than relying upon measurement with an invasive intracoronary pressure wire.”

Despite relying on complex mathematical modelling to provide physiological and anatomical information about diseased coronary arteries, the VIRTUheart technology is designed to be used by clinicians in everyday consultations. As such, it effectively automates a number of advanced computation, modelling and simulation processes, so that all that is needed to use VIRTUheart is an angiogram. Dr Morris says: “We want this tool to be used by clinicians, so it needs to be simple and intuitive. It can’t be reliant on computer scientists.”

The work of VIRTUheart is at the forefront of the ambition of the Insigneo Institute as it represents the realisation of the translation of academic research to clinically useful tools. Already tested on an initial study of 20 patients, it was able to

predict, with 97% accuracy, compared to previous methods, which patients required coronary revascularisation, by stent or surgery and, importantly, which did not. VIRTUheart now aims to widen its test cases and make its system more user friendly, in preparation for a large multi-centre clinical trial. The VIRTU-2 study is collecting data from 100 more patients with coronary artery disease. These patients have more complex coronary disease and will help to develop a useful tool for physicians to use in ‘real-world’ cases. The further cases will also help us to develop the novel individual-patient-tuning system which will improve accuracy on a case by case basis.

Allowing for the completion of this study and the trial of the system, Dr Morris estimates that the technology is about three years from clinical use. Having worked at the juncture of research and healthcare, he has an informed position on the challenges of translating one to the other: “Projects aiming for clinical translation need to focus on what is useful to the clinician, not the scientist. This is why collaborations between the NHS and academic institutions, just like Insigneo are so important. Often clinical medicine does not require what scientists or engineers might consider to be very high levels of model accuracy. Instead, knowing the level of uncertainty for a particular result might be just as useful. Ultimately, a model which demonstrates promise requires a clinical trial in order to encourage uptake and clinical adoption. This is what we are aiming for with our research.”

Projects aiming for clinical

translation need to focus on

what is useful to the clinician, not the scientist.

VIRTUheart simulations of

coronary arteries

Big Data


FEATURE

What is Big Data? Smartphones, tablets and other devices allow us to record and publish increasing amounts of information, and the amount of data in the world continues to increase exponentially, doubling every 18 months. Making sense of huge quantities of data to predict trends and behaviour is an enormous challenge for corporations including Google and Facebook, and the tools for management and analysis of these data are known as Big Data. These data change rapidly, and timely analysis of trends is important. Typically data are not stored in a single location, but distributed over many sites, with analytical processes running independently on multiple data instances to return an aggregated outcome. Recently, these concepts have been extended to the analysis of data from a range of diverse sources, including social media and healthcare.

Why is managing Big Data relevant for healthcare and Insigneo? The ability to combine healthcare records with lifestyle data from social media and mobile devices has the potential to deliver a highly personalised representation of an individual, which would enable targeted, patient specific interventions

and therapy. The combination of Big Data techniques, which capture emerging trends, when the nature of the underlying processes cannot be determined with existing in silico approaches, has the potential to deliver tools that provide a more personalised prediction of outcomes for the patient and enhance the stratification of treatment decisions.

To realise this potential requires a considered approach to data management: to leverage the most powerful analytical methods our data must be well organised from the point at which it is collected or created. In the healthcare domain these requirements bring together the formality required by informatics with the diversity associated with the complexity of the human body and the derived information we use to assess pathophysiology and aid diagnosis and treatment. Whilst information technologies are continually being developed to address even these demanding requirements, successful application of these technologies to healthcare presents a challenge for future research.

What are the challenges and how are we going to meet them? Our vision for big data in healthcare is exciting, but poses significant challenges.

Insigneo members Richard Clayton, Andrew Narracott and Steven Wood discuss the importance of Big Data for in silico medicine

The ability to combine healthcare records with lifestyle data has the potential to deliver a highly personalised representation of an individual, which would enable targeted and patient specific interventions and therapy.


Many of the small-scale biological processes that underlie disease have a stochastic component; there are uncertainties and errors associated with measurements made in the clinic; and many clinical records will have missing data as well as information that is ambiguous and difficult for a computer to interpret. On top of these practical challenges, the increasing volume and complexity of measured data presents a significant challenge, particularly in the area of genomics.

Clearly we are not going to overcome these challenges all at once. Our strategy for Big Data in Insigneo is to develop infrastructure to support research, that includes appropriate design of analytical workflows to ensure the most efficient use of both storage and computational resources. It is important for us to adhere to the ethical and governance standards associated with handling healthcare data, and this aspect is critical to the success of initial research effort and its translation into clinical practice. The partnership between the University and STH, and the inter-sectoral nature of Insigneo membership, provides a solid foundation for fundamental research to be aligned with the requirements of clinical services. Finally, integration of education and training in Big Data techniques with

existing research-led teaching of in silico medicine is essential to ensure the next generation of researchers have the skills to excel within the complex domain of biomedical data-driven simulation.

Where might we be in 5 years time? Looking forward, we expect to remove the barriers between the researcher and state-of-the-art computational infrastructure and analytical methods, which operate over data from the level of the individual to the population as a whole. This will allow computational workflows to be informed by, and contribute to, an evolving body of curated scientific data, which continually refines our understanding of human pathophysiology. A common data infrastructure for academic and clinical researchers, in accordance with appropriate governance, will allow physicians to draw on a broader evidence base than ever before to inform their choice of treatment. We expect the development of personalised approaches to healthcare assessment, diagnosis, stratification and intervention to increasingly rely on a Big Data infrastructure, and we look forward to delivering real benefits by improving the efficiency of healthcare delivery and better healthcare provision to the general public.

Our vision for big data in healthcare is exciting, but poses significant challenges.

18months

Time taken for amount of data in the world to

double

HEALTHCARERECORDS

LIFESTYLEDATA

PERSONALISEDMODELS

PATIENT SPECIFICTREAMENT

Researcher Spotlight:Damien Lacroix


RESEARCHER

What is your current role? As one of the Chairs appointed as part of the creation of Insigneo, I see my role as contributing to the development of the Institute and making it world-leading in the new area of in silico medicine. As Director of Research my aim is to increase the research portfolio of the Institute and enhance internal collaboration within the University and between the many different academics who have some interest in the development of in silico medicine.

What are you working on at the moment?My main research interest is understanding the effect of mechanical loading onto the body. In other words, how our daily physical activity is translated into a series of mechanical stimuli, which are applied to our bodies at different anatomical scales - the organ, tissue, cellular and molecular levels. Since we are constantly doing activities, a better understanding of the influence of loading can enable us to prevent diseases and create personalised rehabilitation programmes in the treatment of neuromusculoskeletal diseases.

Having recently concluded the EC funded MySpine project, what were its outcomes and what did it prove about

the usefulness of in silico modelling in healthcare?During this project we were able to compare the effect of different surgical treatments on lower back pain and advise on the best treatment for individual patients. We were able to predict in a clinical cohort of 200 patients, whether it is better for them to receive pain killers or undergo a surgical treatment. For the first time, an integrated software platform could be operated within a real clinical environment, to help the surgeon make the best decision to treat a given patient. This project was a powerful indicator of how in silico modelling can help in the clinical decision process and therefore improve the treatment of diseases.

You have recently started the EPSRC-Frontier funded project MultiSim, what does this project hope to achieve?This award focuses on the establishment of a currently non-existent but essential computational platform for the management of musculoskeletal disorders. A generic modelling framework that involves multi-scale modelling, unobservable states and variables, and uncertainty will be designed to address various neuromusculoskeletal disorders.

I see my role as contributing to the development of the Institute and making it world leading in the new area of in silico medicine


How significant is the establishment of the Insigneo Institute in Sheffield? The Insigneo Institute is unique in its kind. The integration of modellers and experimentalists within the same place, with the active involvement of clinicians makes this Institute one of the largest and most integrated research institutes in the world devoted to the use of in silico methods for the diagnosis, prognosis, treatment planning and monitoring of diseases in the areas of neuromusculoskeletal, cardiovasculorespiratory, neurosciences and oncology. Insigneo hosts some of the main players of the VPH Community and therefore the Institute is able to act at all levels of in silico medicine going from pre-clinical testing, clinical phase trial, software deployment and data sharing within the hospital to clinical assessment and monitoring of VPH tools. No one else can achieve such integration.

When not working on in silico models, how do you unwind?Family and photography are my two main activities outside work. I love going to the Peak Discrict for a walk with my son and wife and taking pictures.

Damien Lacroix is Professor of Mechanobiology in the Department

of Mechanical Engineering. He has a first degree in Mechanical

Engineering from the National Institute of Applied Science (INSA

Lyon, France) and is Director of Research for the Insigneo Institute.

To read the full interview see www.insigneo.org

Inside Sheffield University’s Pam Liversidge Building,

Insigneo’s state-of-the-art laboratories are enabling

us to be at the cutting edge of in silico research.


LAB FOCUS

InSIDEINSIGNEO


Insigneo LaboratoriesC+ Floor, Pam Liversidge BuildingThe C+ laboratory is a unique environment with specialised equipment, which allows our researchers to work across the range of anatomical scales - organ, tissue, cellular and molecular - when conducting musculoskeletal research. The brand new laboratory is fitted with PCR machines, large mechanical testing machines to compress bone and cells, fluorescence microscopes, atomic force microscopes and more.

Showcase Timetable


Insigneo & Big Data - Why do we Care?10.05, Professor Richard ClaytonRichard Clayton will introduce the topic of Big Data, and explain why the storage and management of large amounts of different types of data is important for Insigneo.

Collecting Contextualised Behavioural Data using everyday Technology10.15, Professor Fabio CiravegnaProf. Dr. Fabio Ciravegna is Professor of Language and Knowledge Technologies and Head of OAK Group in the Department of Computer Science. His research focuses on Information and Knowledge Management, in his talk he will discuss how we can leverage everyday technologies to collect contextualised behavioural data for research purposes.

POLARIS - Polarised and Respiatory Imaging Sheffield10.30, Professor Jim WildProfessor Jim Wild introduces POLARIS - one of Insigneo’s flagship projects. The team behind POLARIS are using state-of-the-art techniques developed in Sheffield to create functional images of the lungs in patients affected by conditions such as smoking, cystic fibrosis, emphysema, pulmonary hypertension and asthma.

The Big Data Panel Debate11.10, Professor Chris NewmanHow can we balance the privacy concerns surrounding the use of Big Data with its potential for public good? Chaired by Chris Newman, Professor of Clinical Cardiology at the University of Sheffield, this discussion is designed to illuminate some of the most pressing

issues surrounding Big Data and its use in medicine today. The panel members are: Pat Lawford, Basil Sharrack, Mark Taylor, Wendy Tindale, Marco Viceconti and Steven Wood.

The Emergence of Computer Aided BioEngineering13.35, Steve Levine, Dassault SystemesBy its very nature, Bioengineering is a complex intersection of multiple disciplines, applying engineering principles to biological systems. DS SIMULIA’s Chief Strategy Officer, Steve Levine will introduce the Living Heart Project and discuss its unique approach to overcoming these challenges.

What a Difference a Donor Makes14.10, David Reynolds, Sheffield Hospitals CharityDavid Reynolds is the Director of the Sheffield Hospitals Charity, the official NHS Charity serving all the NHS Foundation Trusts in Sheffield. The Charity invests between £2-3m annually to make life better for patients in Sheffield. David will talk about the Charity’s partnership with Insigneo and the impact it makes through its grant making and fundraising activities across South Yorkshire.

VPH-Share15.40, Professor Rod HoseAfter four years of work, VPH-Share is ready to launch. The online portal is designed to allow users to quickly develop computational workflows. These chains of processing tasks allow raw medical information to be refined into meaningful diagnostic information. By automating over half the tasks associated with workflow construction, simple workflows can be running within minutes.

TIMETABLE

Welcome to the Insigneo Showcase. What will you discover?


8.45 Arrival, Registrations and Coffee Firth Hall, Firth Court. Exhibition area open

09.30 Welcome Marco Viceconti, Mike Hounslow, David Throssell, Tony Weetman

10.00 Session 1 Richard Clayton, Fabio Ciravegna, Jim Wild

10.45 Coffee Break 11.05 Session 2 - Panel Debate The Big Data Panel Debate: Public Good v Pricacy

12.30 Lunch Buffet Lunch. Exhibition area open

13.30 Session 3 - Industry Perspective Steve Levine, Dassault Systemes SIMULIA

14.05 Session 4 David Reynolds, Commented Posters - Part 1

14.45 Coffee Break 15.10 Session 5 Commented Posters - Part 2

15.35 Session 6 Rod Hose

16.00 Closing Remarks Marco Viceconti

16.15 Exhibition, Drinks Reception & Close Presentation of prize for best abstract

Insigneo Abstracts:Our cutting edge scienceBrowse our posters and hear oral presentations from the best of Insigneo’s cutting-edge research. From more than 50 submissions, from both Insigneo members and students working in association with the Institute, this selection is designed to give you a flavour of our multi-disciplinary work.

Insigneo Project Stands:Up close with our researchDiscover more about our research expertise: get hands-on with VPH-Share’s computing infrastructure; see examples of gait analysis at the MultiSim stand and learn about how they are developing a multiscale hyper modelling framework; and much more…

Facilities and Education:Training the next generationHow will Insigneo help to train the next generation of in silico scientists? Discover more about our Doctoral Training Programme and the opportunities to study with us. From engineering to computing science and medicine, learn about the wide range of areas where in silico methods can be applied.

POLARIS: POLARISED IMAGING

VPH-SHARE: SHARING FOR HEALTHCARE

MULTISIM: FRONTIER ENGINEERING

An Interview with...

Adriano Henney


INTERVIEW

Congratulations on being appointed the new Director of the VPH Institute! Tell us a bit about your background.My first degree was in microbiology, following which I did a PhD in Medicine, researching aspects of cardiovascular pathology. This was the foundation for my interest in pathophysiology and my first experience of working across disciplines. My postdoctoral studies moved me technically from cell biology, through molecular biology and ultimately to leading my own molecular genetics group in Oxford. From there, I was recruited into the pharmaceutical industry where I spent 13 years, before leaving in 2009 to set up independently as a consultant on projects bridging academia and industry.

What is your vision for the VPH Institute?My personal vision is that the VPHi should become recognised as the authoritative, representative voice of the modelling and simulation community engaged in healthcare research and development. The VPHi has been very active at the European level in advocating a greater focus on the application of in silico medicine approaches in research and health policy. My short term plans focus on

maintaining this momentum and using it to raise the profile of the Institute. We have to work hard to promote our identity and provide a compelling reason for industry to become more engaged and contribute financially to create a sustainable foundation for the activities we intend to pursue.

How do you imagine the VPH initiative 10 years from now?The VPHi has the potential to revolutionise medical practice, both directly and through improvements in the delivery of effective biomedical products. The acceptance of these approaches remains limited and it will take time for this to change. We are on the way to achieving that change, and my hope is that within 10 years, examples offering hard evidence of the value of these approaches will be sufficiently compelling to establish VPH technologies in routine practice.

Do you have a message for our members?My message is simply... Be gentle with me and don’t expect too much too fast! I have a lot to learn, but I know that I can call the on VPH community to educate me, fill in the huge gaps in my experience and support me in building on the successes achieved under Marco’s leadership.

We posed the VPH Institute’s new Director with a few pertinent questions

Image: © 2014, Jürgen Lösel

Fact FileName: Adriano HenneyPosition: Programme Director of the Virtual Liver Network, Owner of Obsidian Biomedical Consulting LtdExpertise: Cardiovascular genetics, Vascular biology, Systems biology and Systems medicine

THE LIVING HEART PROJECT A TRANSLATIONAL RESEARCH INITIATIVE TO REVOLUTIONIZE

CARDIOVASCULAR SCIENCE THROUGH REALISTIC SIMULATION

What if doctors leveraged and relied on the same incredible 3D modeling and realistic simulation technology that the automotive, aerospace, energy, and hi-tech industries have used for decades to virtually design, test, and validate products and processes before they have been built or implemented?

Dassault Systèmes, the 3DEXPERIENCE® company that provides business and people with virtual universes to imagine sustainable innovations, has established the Living Heart Project with the aim of making this dream possible for cardiovascular care.

The Living Heart Project was formed to advance the development of safe and effective cardiovascular products and treatments by uniting engineering, scientific, and biomedical expertise to translate cutting edge science into improved patient care. Through simulation and the creation of validated models, the project aims to accelerate the use of science to provide personalized, interventional patient care.

Realistically simulating the behavior of a heart is extremely complex and requires a connection of knowledge from multiple domains, including electrical, mechanical, and fluids.

Over the past three decades, Dassault Systèmes has developed the most advanced modeling and simulation technology available, all of which is now accessible in a single environment that also enables real-time collaboration between medical and engineering professionals and robust data management, and security.

To learn more about the Living Heart Project and how you may be able to contribute, visit: www.3ds.com/heart.

IF WE APPLY THE POWER OF REALISTIC SIMULATION TO HUMAN MODELING, WE CAN REVOLUTIONIZE PATIENT CARE.

40CLINICIANS

The Pam Liversidge BuildingSir Frederick Mappin Building

Mappin StreetSheffield

S1 3JD

+44 (0) 114 222 0162 /5 /[email protected]

139 MEMBERS

51

AFFILIATED PROJECTS

£23M I L L I O N

RESEARCHI N C O M E

29DEPARTMENTS

4RESEARCH AREAS

FIG

URE

S C

ORR

ECT

AT T

IME

OF

WRI

TIN

G

Insigneo Newsletter Spring 2015 - Showcase Edition

Documents

Transcript of Insigneo Newsletter Spring 2015 - Showcase Edition